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Abstract 
 
The poliovirus receptor CD155 and its family member CD112 (nectin-2) are the ligands 
for the activating cell surface receptor DNAM-1 on CD8+ T cells and NK cells.  Here, 
we demonstrated that, while the RMA tumor grew in syngeneic mice, DNAM-1 
ligands-transduced RMA was rejected, in which CD8+ T cells and NK cells played an 
essential role.  Importantly, CD8+ memory cytotoxic T cells to parental RMA were 
generated in these mice.  We found that DNAM-1 was also expressed on CD8α+, 
rather than CD8α-, dendritic cells.  Cross-linking DNAM-1 induced maturation of 
CD8α+ dendritic cells.  Antigen presentation by these stimulated dendritic cells drived 
Th1 cells.  Moreover, the rejection of DNAM-1 ligands-transduced RMA was canceled 
in CD4+ T cell-depleted and MHC class II deficient mice.  Taken together, these 
results suggest that DNAM-1 ligands stimulate innate immunity by CD8α+ dendritic 
cells as well as NK cells, which efficiently prime cell-mediated tumor specific immunity.   
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Introduction 
Immune surveillance is mediated by both cellular and humoral immunities.  
Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells are major players in 
cell-mediated immunity against tumors or virus-infected cells.  CTL and NK cells often 
share adhesion or costimulatory molecules, including CD2 and leukocyte 
function-associated antigen-1 (LFA-1; CD11a/CD18), CD27, 2B4, CD28, inducible 
costimulator (ICOS), NKG2D and others 1,2. These cell surface molecules not only 
mediate intercellular binding between these cytotoxic lymphocytes and target cells, but 
also participate in signal transduction for cytotoxicity and cytokine secretion 1,3.  
DNAM-1 (CD226) is an adhesion molecule that is a member of immunoglobulin 
superfamily containing two Ig-like domains of the V-set 4-6.  DNAM-1 is a ~65 kDa 
glycoprotein expressed on the majority of NK cells, T cells, monocytes and platelets 
and a subset of B lymphocytes 4,7,8.  The monoclonal antibody (mAb) against DNAM-1 
inhibited antigen-specific CTL- and NK cell-mediated cytolysis of some, but not all, 
tumor targets in vitro, suggesting that DNAM-1 is involved in cytotoxicity against certain 
tumor cells expressing the DNAM-1 ligand.  Recently, we and others have identified 
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the poliovirus receptor (PVR) CD155 and its family member CD112 (PVR-related 
family-2 (PRR-2), also called as nectin-2), as the ligands for human DNAM-1 9,10.  
Ectopic expression of human CD155 and/or CD112 rendered tumor cell lines more 
susceptible to IL-2-activated T and NK cell-mediated cytotoxicity in vitro.  While the 
human DNAM-1 ligands CD112 and CD155 are broadly distributed on epithelial and 
endothelial cells in many tissues 11,12, they are over-expressed on certain human 
tumors, including colorectal carcinomas 13, myeloid leukemias 14, and neuroblastomas 
15, suggesting that the DNAM-1 ligands expression is inducible by “stress” such as 
transformation and infection.  However, it has still been an open question how the 
interaction of DNAM-1 with its ligands is involved in immune responses in vivo. 
We have recently identified the murine homologues of DNAM-1 and its ligands 
16.  In the present study, we investigated an in vivo role of DNAM-1 and DNAM-1 
ligands on tumor immunosurveillance.
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Methods 
 
Mice, antibodies and cells 
C57BL/6 (B6) mice were purchased from Charles River Japan and were bred and 
housed under specific pathogen-free conditions. OVA peptide 
(ISQAVHAAHAEINEAGR; OVA323 – 339)–specific CD4+ TCR transgenic mice (OT-II) 
and MHC class II-deficient mice were kindly provided from William R. Heath (WEHI, 
Parkville, Australia) and Diane Mathis (Harvard, Boston), respectively. For depletion of 
CD8+ and CD4+ T cells and NK cells, anti-mouse CD8α (19/178) (a gift from Eiichi 
Nakayama (Okayama University, Japan)), anti-mouse CD4 (GK1.5) and anti-NK1.1 
(PK136) (obtained from ATCC (Manassas, VA) were used.  The other mAbs used in 
this study were purchased from BD Biosciences (San Jose, CA).  RMA cells stably 
expressing mouse CD112α and CD155 (RMA-CD112 and RMA-CD155, respectively) 
were established, as described previously 16. Control RMA cells were also established 
by transducing pMX vector alone and this transduction was confirmed by genomic PCR 
for the vector backbone sequence, using the primers combination of 
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5’-ggtggaccatcctctagact-3’ and 5’-ccctttttctggagactaaat-3’.   Anti-mouse DNAM-1 
(TX-42) mAb was generated in our laboratory by standard methods 16.  TX42 mAb 
was a blocking antibody that inhibited binding of DNAM-1-Fc chimeric protein with 
RMA-CD155 or RMA-CD112, as determined by flow cytometry.  In vivo injection  
(200μg i.p. on day 1 and day 3) of TX42 mAb did not affect the populations of T cells, 
B cells and NK cells in spleen at day 7, as determined by flow cytometry, while 
anti-CD8α (19/178) and anti-NK1.1 (PK136) almost completely depleted CD8+ T cells 
and NK cells, respectively, by the same procedure.  TX42 mAb was free from 
endotoxin, as examined using Limulus amoebocyte lysate (LAL) test (Sigma).   
 
Tumor growth assay and survival of mice 
Groups of five or ten C57BL/6 mice were pretreated by i.p. injection of 200 μg 
mAb for depletion of CD8+ T, CD4+ T or NK cells at day –1, 1, 8, 15 and 22, where day 
0 is the day of primary or secondary tumor inoculation.  Depletion of each cell type 
was confirmed by analyzing splenocytes from a group of mice treated with each mAb.  
For blocking of interaction of DNAM-1 with its ligands in vivo, mice were pretreated by 
  Tahara-Hanaoka et al 
 7 
i.p. injection of 200 μg anti-DNAM-1 at day –1, 1, 6 and 10.  Control mice received the 
equivalent amounts of normal mouse IgG.  At day 0, groups of five or ten mice per 
experiments were injected subcutaneously in the back with 1 x 105 RMA cells which 
were transduced with CD112δ, CD155 or mock-control vector.  Mice were examined 
twice a week for tumor size with a caliper square.  For the re-challenge experiments, 
mice that had completely rejected the initial tumor cells were injected with 
mock-transduced RMA tumor cells 70 days after the first tumor inoculation.   
 
ELISPOT assay 
ELISPOT assay was performed with a mouse IFN- γ -specific ELISPOT kit 
(e-Bioscience, San Diego, CA) according to the manufacturer’s instructions. 
Splenocytes from naïve C57BL/6 mouse were used as an antigen presenting cells 
(APC) after pulse with 1 μM gagL peptide  (CCLCLTVFL; gagL75-83), which is a 
leader sequence of Rauscher murine leukemia virus, or a control OVA peptides 
(SIINFEKL; OVA257-264) for 30 min at 37℃, and then plated at 5 x 106 cells/well. CD8+ T 
cells from splenocytes of mice inoculated with RMA-CD155 or RMA-mock were 
purified by positive selection using MACS (Miltenyi Biotech, Auburn, CA) according to 
the manufacturer’s instructions, and plated across a range of cell concentrations to 
achieve 10 to 100 spots/well for accurate counting, and cultured for 24 hours with APC 
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pre-pulsed with peptides. The colored spots were counted using a stereomicroscope. 
Frequencies of antigen-specific IFN-γ-secreting cells were calculated based on the 
numbers of CD8+ cells and the number of spots per well after subtraction of 
background, which was obtained by incubating CD8+ T cells stimulated with the control 
OVA peptides. Experiments were performed in triplicate. 
 
In vitro stimulation of DC 
CD11c+ DC was purified from spleen cells of C57BL/6 mice by positive 
selection using MACS (Miltenyi Biotech, Auburn, CA).  Cells were incubated with 
anti-CD16/32 mAb (2.4G2) to block non-specific binding to Fcγ receptors by antibodies 
and then stimulated with plate-coated control Ig or anti-mDNAM-1 (TX-42) for 4 days.  
Cells were then stained with PE-conjugated anti-CD11c mAb, APC-conjugated 
anti-CD8 mAb and either FITC-conjugated anti-CD80, anti-CD86, anti-MHC class II 
(I-Ab) mAbs or control IgG and analyzed by flow cytometry.  For analysis of function of 
DNAM-1-expressing DC, CD11c+CD8α+ or CD11c+CD8α- DCs were purified from 
splenocytes of C57BL/6 mice by positive selection by using MACS and then by flow 
cytometry.  Each DC population was stimulated with plate-coated anti-DNAM-1, 
anti-CD40 or control Ig for 4 days.  Cells were pulsed with the OVA peptide and then 
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co-cultured with CD4+ T cells from splenocytes of OT-II mice for 7 days.  Cells were 
then stimulated with anti-CD3 and anti-CD28 for 48 hours, and IFN-γ concentrations in 
the culture supernatants were determined with a mouse IFN-γ-specific ELISA kit 
(Biosource International, Camarillo, CA).  
 
Immunohisotochemistry 
Immunostaining was performed with some modifications as previously 
described17.  Six-micrometer cryostat sections were processed for 
immunohistochemical procedures based on the Labeled Polymer method (DAKO 
Japan, Kyoto, Japan).  Briefly, sections were treated with 3% hydrogen peroxidase in 
absolute methanol for 30 minutes to quench endogenous peroxidase activity.  After 
antigen retrieval with Target Retrieval Solution (DAKO Japan), sections were 
preincubated in 0.01M PBS containing 5% normal goat serum (Jackson Immuno 
Research, West Grove, PA) at room temperature (RT) for 1 hr, and then incubated in 
anti-PRR-2 mAb (1:20 dilution) containing 0.5% bovine serum albumin (BSA) at RT for 
2 hrs.  After washes with 0.1M PBS, the sections were incubated in goat anti-mouse 
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Ig conjugated to peroxidase-labeled dextran polymer (EnVision+, DAKO Japan) at RT 
for 30 min.  After washes with 0.1M PBS, the horseradish peroxidase reaction was 
developed in 0.1M Tris-buffered saline, pH 7.4, containing 0.05% 
3,3'-diaminobenzidine tetrahydrochloride (Sigma), 0.02% nickel sulfate, and 0.01% 
hydrogen peroxide.  Methyl green was used for counterstaining. The following 
controls were performed: (i) incubation with isotype control antibody instead of the 
primary antibody; (ii) incubation without the primary antibody or without primary and 
secondary antibodies.  All controls revealed no signals.  
 
Quantitative RT-PCR 
Total RNA was extracted from gastric cancer tissues and the adjacent normal 
tissues in three patients with poorly-differentiated gastric cancer with ISOGEN reagent 
(Nippongene, Japan).  Reverse transcription was performed with 5 μg of total RNA 
using Thermoscript RT-PCR System and 50 ng of random hexamers (Invitrogen) in a 
final volume of 20 μl.  Real-time PCR analysis of CD112 was carried out on an 
ABI7700 sequence detector (Applied Biosystems, Foster City, CA).  The primers for 
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CD112 were as follows: upper primer, 5'- atg tgg ccg cct tcc acc cta a-3'; lower primer, 
5'-cag act gtc cac tgc gtg gat g -3'. The 18 S rRNA level was measured as an internal 
control (upper primer, 5'-ccc tgc cct ttg tac aca cc-3'; lower primer, 5'-cga tcc gag ggc 
ctc act a-3').  The thermal cycling conditions comprised an initial denaturation step at 
95oC for 10 min, followed by 40 cycles at 95oC for 15 s and 60oC for 1 min. Standard 
curves were generated using serial dilutions of cDNA from HOS cells (human 
osteosarcoma cell line), covering 4 orders of magnitude and yielding correlation 
coefficients of at least 0.98 in all experiments. Each standard and sample value was 
determined in triplicate in three independent experiments.  In each experiment, 
CD112 expression under a given experimental condition was calculated relative to the 
control condition. 
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RESULTS  
Expression of the DNAM-1 ligand on human poorly-differentiated gastric cancer 
Recent evidences indicate that the DNAM-1 ligands CD155 and CD112 are 
over-expressed on certain human tumors, including colorectal carcinomas, 
neuroblastomas and myeloid leukemias 13-15.  We also investigated the expression of 
the DNAM-1 ligand CD112 on specimens from five patients with gastric cancer, 
including two well-differentiated and three poorly-differentiated histological types, and 
two patients with colon cancer.  Immunohistochemical analyses demonstrated that 
CD112 was over-expressed preferentially in the poorly-, but not well-, differentiated 
histological type of gastric cancer (Fig 1a).  We could not clearly detect CD112 in the 
untransformed normal tissue area bordering transformed cancer tissue in each 
specimen.  To further assess whether CD112 is specifically expressed in 
poorly-differentiated cancer tissue but not in normal gastric tissue, we divided the 
gastric tissues resected under surgery into transformed and normal areas of slices and 
compared mRNA expression of CD112 in each patient by quantitative RT-PCR analysis.  
As shown in Fig 1b, relative amount of CD112 mRNA expressions are about three 
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times higher in the poorly-differentiated gastric cancer compared with that in normal 
gastric tissue in all the three patients.  We also observed the over-expression of 
CD112 on colon cancer as well (Fig 1a).  These observations, along with the recent 
reports 13-15, suggest that DNAM-1 ligands can be targets for tumor 
immunosurveillance in vivo.   
 
RMA tumor expressing DNAM-1 ligands is rejected in mice 
To investigate the in vivo consequences of DNAM-1 ligands expression on 
tumor cells, B6 mice were inoculated subcutaneously with a murine T cell lymphoma 
RMA transfected with control vector (RMA-mock) or CD112 (RMA-CD112).  Whereas 
mice injected with 1 x 105 RMA-mock all developed tumors and died by 55 days after 
tumor inoculation, most mice rejected the same number of RMA-CD112 (Fig 2A).  
These recipient mice of RMA-CD112 survived significantly longer than those of 
RMA-mock (Fig 2A).  Similarly, most mice rejected 1 x 105 RMA trasfected with 
CD155 (RMA-CD115) and survived more than 175 days (Fig 2B).  Since all these 
RMA transfectants showed similar growth kinetics in vitro, as determined by BrdU 
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incorporated proliferation assay (data not shown), these results indicate that ectopic 
expression of DNAM-1 ligands can result in rejection of tumors in syngeneic mice.  
 
CD8+ T cells are responsible for the rejection of DNAM-1 ligands-transduced 
RMA cells 
DNAM-1 is strongly expressed on the majority of CD8+ T cells and mediates a 
costimulatory signal in antigen-specific CD8+ T cells in vitro 4,16.  We therefore 
investigated whether CD8+ T cells were responsible for the rejection of RMA 
expressing DNAM-1 ligands.  Mice were treated in vivo with depleting monoclonal 
antibodies specific for CD8 or with a control antibody and then inoculated with RMA 
transfectants.  Depletion of CD8+ T cells completely canceled the tumor rejection of 
both RMA-CD155 and RMA-CD112, and these mice became moribund at the same 
time as recipients of RMA-mock (Fig 2C, D).  These results indicated that CD8+ T 
cells were essential for the rejection of DNAM-1 ligands-transduced RMA tumors.  
Colonna and colleagues have recently identified the T cell-activated increased 
late expression (Tactile) (also called as CD96), which is expressed on activated T cells 
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18, as another receptor ligand for human CD155 19.  However, it is unclear whether the 
mouse homologue of CD96 is also a receptor for mouse CD155 or CD112, although it 
has not yet been identified.  To confirm that DNAM-1, but not putative murine CD96, is 
responsible for the rejection of DNAM-1-ligands-expressing RMA tumors, we 
generated an anti-DNAM-1 mAb (TX42) that was able to block the ligand binding in 
vitro (Fig 3A).  Mice were pretreated in vivo with TX42 mAb, which did not deplete T 
cells and NK cells in vivo (Fig 3B), and then inoculated subcutaneously with 
RMA-CD155. Eight days after tumor inoculation when tumors had not yet grown 
enough to be visible on the skin, the skin regions was resected and subjected to 
histological analyses.  Whereas RMA-mock substantially proliferated in the skin 
region, most RMA-CD155 appeared to be dead (Fig 3C).  However, pretreatment with 
anti-DNAM-1 mAb restored RMA-CD155 growth (Fig 3C), and the survival of these 
mice was significantly shorter than that of mice pretreated with control Ig (Fig 3D).  
Similar results were observed in mice inoculated with RMA-CD112 (data not shown).  
Because TX42 mAb did not affect the lymphocytes population in vivo, these results 
suggested an essential role of DNAM-1 on CD8+ T cells in the tumor rejection. 
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Induction of memory CD8+ T cells in mice inoculated with DNAM-1 
ligand-expressing RMA 
 To investigate whether DNAM-1 ligands expression on RMA induces T 
cell-mediated immunological memory, mice that had previously rejected the 
CD155-tranfected RMA tumor cells were re-challenged with the parental RMA tumors 
70 days after the first inoculation (Fig 4).  Whereas RMA-mock grew and killed all 
naïve mice after the first inoculation, they were rejected in all the mice that had once 
rejected RMA-CD155 (Fig 4).  However, depletion of CD8+ T cells with in vivo 
injection of anti-CD8 mAb before the re-challenge canceled the rejection of RMA (Fig 
4).  These results suggest that CD8+ memory T cells specific for an RMA 
tumor-associated antigen were generated in mice inoculated with RMA-CD155.   
  RMA is a Rauscher murine leukemia virus-transformed cell line bearing H-2Db, 
which associates with a peptide derived from the gag leader (gagL) sequence of the 
virus recognized by CTL as an epitope 20,21. To investigate whether CD8+ T cells 
generated in mice inoculated with RMA-CD155 were specific to the gagL peptide, we 
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isolated CD8+ T cells from spleen in mice after inoculation with RMA-mock or 
RMA-CD155, stimulated the CD8+ T cells in vitro with the gagL peptide and 
determined the frequency of the peptide-specific IFN-γproducing CD8+ T cells by 
ELISPOT assay.  Although we could not detect CD8+ T cells that responded to the 
gagL peptide in mice immunized with RMA-mock or RMA-CD155 at the priming phase 
around day 3~5 after the tumor challenge by this assay (data not shown), mice 
inoculated with RMA-CD155 generated CD8+ T cells responsive to the gagL-peptide 
significantly more than those inoculated with RMA-mock at day 14 to 18 when 
RMA-mock tumor become visible (Fig 4B).  These results suggested that the gagL 
peptide-specific CD8+ T cells might play an important role for efficient tumor rejection 
of RMA-CD155 and memory CTL induction.      
 
NK cells are also involved in the tumor rejection  
 DNAM-1 is expressed on NK cells and involved in NK cell-mediated 
cytotoxicity and cytokine secretion in vitro 4,9.  We therefore examined whether NK 
cells are also involved in the rejection of RMA-CD155 and RMA-CD112 that express 
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MHC class I (H-2b).  As demonstrated in Figs 2E and F, depletion of NK cells with 
anti-NK1.1 mAb partially canceled the tumor rejection of RMA-CD112 and RMA-CD155, 
indicating that NK cells were in part involved in the tumor rejection.  These results 
suggested that NK cells might be directly activated by DNAM-1 ligand-expressing 
RMA.   
 
DNAM-1-mediated signal induces maturation of CD8α+ dendritic cells 
In a detailed study of mouse DNAM-1 expression on immune cells using our 
newly generated anti-DNAM-1 mAb, we found that a subset of CD11c+ cells also 
expressed DNAM-1.  Further examination demonstrated that DNAM-1 was 
preferentially expressed on CD8α+, rather than CD8α-, CD11c+ dendritic cells (DC) in 
spleen (Fig 5A), suggesting that DNAM-1 ligands may stimulate also this subset of DC.  
To examine this possibility, CD11c+ cells were purified from spleen by MACS sorting, 
stimulated with plate-coated anti-DNAM-1 mAb and then stained with anti-CD11c, 
anti-CD8α and either anti-CD80, anti-CD86 or anti-MHC class II.  As demonstrated in 
Fig 5B, cross-linking DNAM-1 with anti-DNAM-1 mAb induced up-regulation of CD80, 
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CD86 and MHC class II expressions in CD8α+, but not CD8α-, CD11c+ cells, 
indicating that DNAM-1-mediated signal induces maturation of CD8α+ DC.   
 
CD4+ T cells are also involved in the tumor rejection 
CD8α+ DC is a functionally specialized subpopulation (reviewed in Shortman, 
K., et al 22), which produces much higher level of IL-12 p70 than CD8α- DC population 
and is involved in Th1 differentiation from naïve helper T cells 23,24.  Therefore, we 
assumed that antigen presentation by MHC class II of these stimulated CD8α+ DC 
drives differentiation of antigen-specific helper T cells into Th1 cells.  To test this 
hypothesis, CD4+ T cells purified from OVA-specific TCR transgenic mice were 
co-cultured with OVA-peptide-pre-pulsed CD8α+ or CD8α- DC that had been 
stimulated with anti-DNAM-1 mAb.  We observed that interferon (IFN)-γ secretion was 
significantly increased in culture of CD4+ T cells with CD8α+, but not CD8α-, DC 
stimulated with anti-DNAM-1 mAb (Fig 5C), indicating that DNAM-1 on CD8α+ DC is 
involved in Th1 polarization.  These results suggested that not only CD8+ T cells but 
also CD4+ T cells might play an important role for tumor rejection of RMA-CD112 or 
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RMA-CD155.  In fact, depletion of CD4+ T cells with anti-CD4 mAb partially canceled 
the rejection of RMA-CD112, leading to shorter survival of mice without CD4+ T cells 
than those with CD4+ T cells (Fig 2A, G).  Similarly, the survival of mice deficient in 
MHC class II was significantly shorter than those of wild type mice after inoculation with 
RMA-CD112 (Fig 2A, F).   
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DISCUSSION 
The DNAM-1 ligands are constitutively expressed at low levels on epithelial 
and endothelial cells.  In the present study, we have shown that the DNAM-1 ligand 
CD112 is over-expressed on human gastric and colon cancers.  There are also 
evidences that the DNAM-1 ligands expression is up-regulated on human tumors, 
including colorectal carcinomas, neuroblastomas and myeloid leukemias 13-15.  These 
observations suggest that the DNAM-1 ligands expression may be inducible by “stress” 
such as transformation, leading us to examine whether these ‘stress-inducible 
self-ligands’ may potentially stimulate innate and/or adaptive tumor immunity.  Here, 
we have demonstrated that ectopic expression of DNAM-1 ligands permitted rejection 
of RMA tumors inoculated in mice.  CD8+ T cells played an essential role for the 
rejection of the DNAM-1 ligand-expressing RMA tumors.   
Several lines of evidences have demonstrated that innate immune 
surveillance is important for efficient priming of adaptive anti-tumor immunity 25.  
Several cell surface receptors, including CD27 and NKG2D, expressed on NK cells 
have been reported to induce the primary and secondary tumor rejections by NK cells 
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and CD8+ memory T cells, respectively 26,27, suggesting a link between innate and 
adaptive immunities.  Although both human and mouse DNAM-1 are expressed on 
NK cells and involved in NK cell-mediated cytotoxicity and interferon (IFN)-γ secretion 
in vitro 4,9, it remained undetermined whether DNAM-1ligands on tumors that bear 
MHC class I could stimulate NK cells in vivo in spite of inhibitory signals in NK cells 
mediated by MHC class I receptors.  In the present study, we have demonstrated that, 
although RMA tumor expresses MHC class I (H-2b), NK cells seemed to be partially 
responsible for rejection of RMA expressing the DNAM-1 ligands.  It was likely that NK 
cells were directly activated by DNAM-1 ligand-expressing RMA tumors and produced 
cytokines, such as interferon (IFN)-γ and/or IFN-α an efficient 
priming of adaptive immunity. 
One of the most notable findings in the present study was that CD8α+, but not 
CD8α-, DC substantially expressed DNAM-1 and cross-linking DNAM-1 with 
anti-DNAM-1 mAb induced maturation of CD8α+ DC in vitro.  Importantly, the CD8α+ 
DC is a functionally specialized subpopulation (reviewed in 22).  They produces much 
higher level of IL-12 p70 than CD8α- DC populations 23,24, resulting in differentiation of 
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Th1 cells that facilitate cell-mediated immunity.  In fact, our study showed that antigen 
presentation by CD8α+ DC stimulated with anti-DNAM-1 drived Th1 cells.  It was of 
note, however, that depletion of CD4+ T cells or deficiency of MHC class II did not 
completely canceled the tumor rejection of RMA-CD112, indicating that CD4+ T cells 
are not necessarily required for the tumor rejection.  Recent evidences have 
demonstrated that CD8α+ DC selectively endocytosis dying cells in vivo 28, and can 
cross-present exogenous antigens on MH C class I 29,30, resulting in priming CTL 31.  
Therefore, it was also likely that the CD8α+ DC carried out the uptake of tumor debris 
destroyed by NK cells and directly stimulated CD8+ T cells resulted by 
cross-presentation of a tumor-associated antigen.  
We have demonstrated that CD8+ T cells specific to the Rauscher murine 
leukemia virus-derived gagL peptide antigen were generated in mice immunized with 
DNAM-1 ligand-transduced RMA significantly more than those immunized with 
mock-transduced RMA.  Moreover, cross-linking DNAM-1 induced maturation of 
CD8α+ dendritic cells.  Antigen presentation by these stimulated dendritic cells drived 
Th1 cells and CD4+ helper T cells were involved in tumor rejection.  Taken together, 
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these results suggested that DNAM-1 ligand expression on RMA may play an 
important role for priming of the gagL peptide-specific CD8+ CTL.  However, we still 
cannot reach this conclusion by these data at present, because we could not directly 
detect CD8+ T cells that responded to the peptide in the early days of priming around 
day 3~5 after tumor challenge by the ELISPOT assay, and therefore could not exclude 
a possibility that proliferation of the gagL peptide-specific CD8+ T cells were affected in 
mice inoculated with RMA-mock by an immuno-suppressive effect of growing RMA 
tumor.  Nonetheless, the present studies suggested that interaction of DNAM-1 and 
DNAM-1 ligands played an important role for tumor rejection mediated by the RMA 
tumor-associated antigen-specific CD8+ T cells.   Although we observed most tumor 
cell lines, except RMA, expressed the DNAM-1 ligands, whether these tumors are 
rejected in vivo may depend on expression of tumor antigen specifically recognized by 
CD8+ T cells.   
 In summary, the present study proposes a model that DNAM-1 ligands, whose 
expression are inducible on tumors, potentially trigger innate immunity mediated by NK 
cells and CD8α+ DC, both of which further stimulate each other by cytokines produced 
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by themselves such as IFN-α, IFN-γ, IL-12, IL-15 and IL-18 32.  CD8α+ DC then 
captures tumor debris destroyed by NK cells and present a tumor-associated antigen 
on both MHC class I and class II, resulting in priming antigen-specific CD8+ and CD4+ 
T cells.  Further studies should be required to clarify molecular and cellular 
mechanisms of DNAM-1-mediated tumor immunity.  
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Figure Legends 
Figure 1. Upregulation of CD112 expression in gastric and colon cancers 
(A) Specimens from human gastric and colon cancer tissues were stained with 
anti-CD112 mAb (TX31).  Positive signals were observed in the 
poorly-differentiated (black arrow), but not well-differentiated (white arrow), 
transformed epithelial cells in gastric cancer (left).  The transformed epithelial 
cells also show the highly positive signal (black arrow) in colon cancer (right).   
(B) mRNA was obtained from gastric cancer tissues from three patients with 
poorly-differentiated histological type.  In each patient, mRNA was also obtained 
from untransformed normal tissue area.  RT-PCR was performed with 
CD112-specific primers and the amount of cDNA was measured by quantitative 
PCR analysis.  CD112 mRNA expression was normalized to the internal standard 
18S ribosomal RNA. 
 
Figure 2. Rejection of DNAM-1 ligands-expressing RMA tumor cells  
Groups of five C57BL/6 mice were pretreated with control Ig or monoclonal antibodies 
  Tahara-Hanaoka et al 
 30 
indicated at day –1, 1, 8, 15 and 22.  The mice were inoculated s.c. in the back at day 
0 with 1 x 105 mock-transduced RMA tumor cells (open symbols) or CD112- or 
CD155-transduced RMA tumor cells (closed symbols). Survival data for five mice per 
group are shown.   
 
Figure 3. DNAM-1 is involved in rejection of DNAM-1 ligands-expressing RMA 
tumor cells 
CD155-RMA and CD112-RMA were stained with DNAM-1-Fc chimeric protein, which 
had been incubated with an excess of TX42 mAb (bold line) or control IgG (thin line), 
and then analyzed by flow cytometry. Staining with control human IgG1 (dotted line) 
and blocking of the DNAM-1 Fc staining with an excess of TX42 mAb (bold line) or 
control IgG (thin line) was performed to show the inhibitory function of TX42 mAb for 
DNAM-1 ligands recognition (A).  Splenocytes from mice were stained with 
FITC-conjufated anti-CD3 and PE-conjugated DX5 and analyzed 7 days after injection 
with TX42 mAb (200μg i.p. on day 1 and day 3) by flow cytometry (B).  Groups of five 
C57BL/6 mice were pretreated with control Ig or anti-mDNAM-1 mAb at day –1.  The 
mice were inoculated s.c. in the back at day 0 with 1 x 105 mock-transduced RMA 
tumor cells or CD155-transduced RMA tumor cells.  The skin regions were subjected 
to histological analysis with hematoxilin-eosin under light microscopy at day 8.  Data 
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are representative from three mice in each group (C).  Survival data for five mice per 
group are shown (D).   
 
Figure 4. Memory CD8+ T cell induction specific to RMA by the DNAM-1 ligands 
(A) Groups of ten C57BL/6 mice were primarily inoculated with mock-transduced or 
CD155-transduced RMA tumor cells.  Mice that had rejected 1 x 105 
CD155-transduced RMA tumor cells were divided into two groups and pretreated 
(i.p.) either with anti-CD8 mAb or control Ig, and re-challenged s.c. in the back with 
1 x 105 parental RMA tumor cells at 70 days after the primary tumor inoculation.  
Tumor size in each mouse was measured twice a week and the mean values were 
plotted.   
(B) CD8+ T cells were separated from spleen in mice 14 to 18 days after inoculation 
with RMA-mock or RMA-CD155 and stimulated in vitro with gagL peptide in the 
presence of splenocytes that were used as APC.  The frequency of the 
peptide-specific CD8+ T cells, defined as Interferon-γ− , 
w determined by ELISPOT assay, as described in Materials and Methods.  
The error bars indicate 1SD.  
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Figure 5.  DNAM-1-mediated signal induces maturation and activation of 
CD8α DC  
(A) Spleen cells from C57BL/6 mice were stained with PE-conjugated anti-CD11c, 
FITC-conjugated anti-CD8 and biotin-conjugated anti-DNAM-1, followed by 
APC-conjugated streptavidin.  DNAM-1 expressions on CD8α−CD11c+ and 
CD8α+CD11c+ cells were analyzed by flow cytometry. 
(B) CD11c+ DCs were separated from splenocytes of C57BL/6 mice by positive 
selection by using MACS.  Purified DCs were stimulated for 4 days with plate-coated 
anti-DNAM-1 mAb or control IgG, and stained with anti-CD11c, anti-CD8 and either 
control Ig, anti-CD80, anti-CD86 or anti-MHC class II (I-Ab).  Mean fluorescence 
intensity of CD80, CD86 and I-Ab expressions on CD8+CD11c+ or CD8- CD11c+ DCs 
were determined by flow cytometry.  Data are representative in several independent 
experiments.   
(C) CD11c+CD8α+ or CD11c+CD8α- DCs were stimulated with plate-coated mAbs 
indicated for 4 days, pulsed with the OVA peptide and then co-cultured with CD4+ T 
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cells from splenocytes of OT-II mice for 7 days.  CD4+ T cells were stimulated with 
anti-CD3 and ant-CD28 for 48 hours and IFN-γ concentrations in the culture 
supernatant were determined by ELISA.  Data are representative in several 
independent experiments.   
 
 
 
 
 
 
 
